v3.26.1
Consolidated Statements of Changes in Equity (Capital Deficiency) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
AOCI Attributable to Parent [Member]
Treasury Stock, Common [Member]
Retained Earnings [Member]
Parent [Member]
Noncontrolling Interest [Member]
Total
Balance at Dec. 31, 2022 $ 3 $ 150,355 $ (270) $ (1,266) $ (121,261) $ 27,561 $ 1,510 $ 29,071
Balance, shares at Dec. 31, 2022 2,554,356              
Stock-based compensation to employees and directors 415 415 415
Issuance of warrants with respect to convertible loans 449 449 449
Extinguishment in connection with convertible loan restructuring 287 287 287
Issuance of shares and warrants net of issuance costs [1] 5,283 5,283 5,283
Issuance of shares and warrants net of issuance costs, shares 535,764              
Issuance of Shares due to exercise of warrants [1]
Issuance of Shares due to exercise of warrants, shares 97,369              
Comprehensive income (loss) for the period (49) (55,361) (55,410) (150) (55,560)
Stock-based compensation to service providers 48 48 48
Deconsolidation of Octomera 9,406 384 9,790 (1,360) 8,430
Adjustment to redemption value of redeemable non-controlling interest (9,406) (9,406) (9,406)
Balance at Dec. 31, 2023 $ 3 156,837 65 (1,266) (176,622) (20,983) (20,983)
Balance, shares at Dec. 31, 2023 3,187,489              
Stock-based compensation to employees and directors 359 359 359
RSUs vested [1]
RSUs vested, shares 12,410              
Exercise of options [1] 13 13 13
Exercise of options, shares 25,519              
Issuance of shares to service providers [1] 1,629 1,629 1,629
Issuance of shares to service providers, shares 119,896              
Exchange of convertible loans for equity $ 1 20,310 20,311 20,311
Exchange of convertible loans for equity, shares 1,577,694              
Issuance of warrants with respect to convertible loans 1,459 1,459 1,459
Extinguishment in connection with convertible loan restructuring 5,421 5,421 5,421
Issuance of shares and warrants net of issuance costs [1] 2,496 2,496 2,496
Issuance of shares and warrants net of issuance costs, shares 242,272              
NCI arising from Octomera reconsolidation 408 408
Transaction with NCI (see note 3)   (408) (408) 408
Issuance of Shares due to exercise of warrants $ 1 47 48 48
Issuance of Shares due to exercise of warrants, shares 6,026              
Comprehensive income (loss) for the period 319 (48,165) (47,846) (848) (48,694)
Balance at Dec. 31, 2024 $ 5 $ 188,163 $ 384 $ (1,266) $ (224,787) $ (37,501) $ (32) $ (37,533)
Balance, shares at Dec. 31, 2024 5,171,306              
[1] Represents an amount lower than $1